Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASSANDRA: Short-course vs Long-course Pre-operative Chemotherapy in PDAC
NCT04793932Phase 3Active, not recruiting
- Sponsor
- Associazione Italiana per lo Studio del Pancreas
- Start
- Nov 2020
- Primary completion
- Mar 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of PAXG and mFOLFIRINOX in pancreatic ductal adenocarcinoma (PDAC) (4 arms), sponsored by Associazione Italiana per lo Studio del Pancreas. Primary endpoint: Event-free survival at 12 weeks. Started Nov 2020; status: active, not recruiting.
02
Drugs
PAXGmFOLFIRINOX
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04793932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793932.